Pharmaceuticals News and Research

RSS

Health and defense applications account for 40% of business R&D: NSF report

Businesses in the United States are focusing a large portion of their research and development efforts on health and defense, according to a National Science Foundation (NSF) report released today.

27 Aug 2012

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Novira Therapeutics Inc. today announced it has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

24 Aug 2012

Proposed U.S. legislation would 'set the standard' for global efforts to combat counterfeit drugs

In this Forbes opinion piece, John Lechleiter, president and chief executive officer of Eli Lilly and Company, examines the business of counterfeit medicines, writing, "With global sales last year estimated as high as $200 billion, counterfeit medicine is big business, and it's growing."

24 Aug 2012

NCKU research team identifies Au nanorod complex for cancer therapy

A National Cheng Kung University (NCKU) research team has discovered Near-Infrared Light-Responsive oligonucleotide-gated Au nanoensembles (Au nanorod complex), a potent new anti-cancer complex that is seen as a promising targeted therapy for curing cancer.

24 Aug 2012

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.

24 Aug 2012

FDA approves Watson’s ANDA for lidocaine topical patch 5%

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm.

24 Aug 2012

Positron submits Drug Master File with FDA for production of API grade Sr-82

Positron Corporation, a leading molecular imaging healthcare company, is pleased to announce the submission of a Drug Master File (DMF), with the Federal Drug Administration (FDA), for the production of Active Pharmaceutical Ingredient (API) grade strontium-82, through its wholly owned subsidiary Manhattan Isotope Technology, LLC.

23 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Mylan, Pfizer partner to develop and market generic drugs in Japan

Pfizer Inc. and Mylan Inc. today announced that they have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. The collaboration is designed to build upon each company's highly complementary strengths and quality assets.

23 Aug 2012

EMD Millipore enters definitive agreement to acquire Biochrom

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.

From Biochrom Ltd. 23 Aug 2012

UC San Diego, iSAEC partner to study genetics of drug induced renal injury

The International Serious Adverse Events Consortium (iSAEC) announced today it will collaborate with the University of California, San Diego School of Medicine and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Science to research the genetics of drug induced renal injury (DIRI).

22 Aug 2012

FDA warns consumers about potential health risks of two natural dietary supplements

The U.S. Food and Drug Administration today issued a new warning to consumers about the potential health risks of two products marketed as natural dietary supplements for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions.

22 Aug 2012

FDA committee to review NPS’ Gattex NDA in October

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012.

22 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Wockhardt receives final FDA approval for Felodipine ANDA to treat hypertension

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used in treating hypertension.

22 Aug 2012

Study highlights Nek9 protein as decisive factor in cell division

A study by the Institute for Research in Biomedicine (IRB Barcelona) and the Center for Genomic Regulation (acronym in Catalan CRG) highlights the protein Nek9 as a decisive factor in cell division, a fundamental process for both the development of an organism and tissue maintenance.

22 Aug 2012

Bile duct cancer chosen as next indication for PCI Biotech

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has chosen bileduct cancer as the next indication for the use of its PCI (photochemical internalisation) localised cancer therapy. In this indication PCI Biotech’s proprietary photosensitiser Amphinex® will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to start the clinical Proof of Concept study within end of 1H 2013.

21 Aug 2012

DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies

Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has signed an agreement with DPT Labs to commence work on supplying Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for currently planned Phase 3 clinical trials.

21 Aug 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012